P48.23 Exposure-Response Analyses and Clinical Utility Index to Justify the Dosage of Lurbinectedin in Small-cell Lung Cancer

Lurbinectedin (Zepzelca™) received accelerated approval by the US FDA for the treatment of adults with small-cell lung cancer (SCLC) with disease progression on or after platinum-based chemotherapy. The analyses presented herein characterized the relationships between lurbinectedin plasma exposure and efficacy or safety, which justify the selected dose regimen of 3.2 mg/m2 administered every 3 weeks (q3wk).